反応式
Brc1ccc(I)cc1.C1CCN(C2CCNCC2)CC1>CC(C)(C)[O-].CC1(C)c2cccc(P(c3ccccc3)c3ccccc3)c2Oc2c(P(c3ccccc3)c3ccccc3)cccc21.Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd]>Brc1ccc(N2CCC(N3CCCCC3)CC2)cc1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 80 °C
実験手順
TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (0.162 g, 0.18 mmol) was added to 1,4'-bipiperidine (0.595 g, 3.53 mmol), 1-bromo-4-iodobenzene (1.000 g, 3.53 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.205 g, 0.35 mmol) and sodium 2-methylpropan-2-olate (0.408 g, 4.24 mmol) in toluene (10 mL). The resulting mixture was degassed again and was stirred at 80 °C for 18 hours under nitrogen. The reaction mixture was cooled to room temperature and filtered then the filtrate was diluted with EtOAc (50 mL), and washed sequentially with water (50 mL), water (50 mL), and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 1'-(4-bromophenyl)-1,4'-bipiperidine (0.736 g, 64.4 %) as a pale brown oil.
出典と根拠
- ORDレコード
- ord-1342ffbeb4634245a6963094cc9535b6
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…